Assessing the efficacy and safety for novel drug candidates for Alzheimer's disease employs a rigorous evaluation framework. Preclinical studies typically involve in vitro and in vivo assays to assess the potential ability in targeting disease-related pathways. Once promising candidates emerge, they progress through clinical trials these are condu